DK2839004T3 - Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation - Google Patents
Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation Download PDFInfo
- Publication number
- DK2839004T3 DK2839004T3 DK13721452.4T DK13721452T DK2839004T3 DK 2839004 T3 DK2839004 T3 DK 2839004T3 DK 13721452 T DK13721452 T DK 13721452T DK 2839004 T3 DK2839004 T3 DK 2839004T3
- Authority
- DK
- Denmark
- Prior art keywords
- islands
- transplantation
- procedure
- term
- long
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2839004T3 true DK2839004T3 (da) | 2019-07-01 |
Family
ID=48326412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13721452.4T DK2839004T3 (da) | 2012-04-18 | 2013-04-18 | Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (da) |
| EP (1) | EP2839004B1 (da) |
| JP (2) | JP6348484B2 (da) |
| KR (1) | KR20150003824A (da) |
| CN (2) | CN104487574B (da) |
| AU (1) | AU2013249191B2 (da) |
| CA (1) | CA2870547A1 (da) |
| DK (1) | DK2839004T3 (da) |
| ES (1) | ES2732252T3 (da) |
| HK (1) | HK1207117A1 (da) |
| IN (1) | IN2014DN08158A (da) |
| MX (1) | MX370149B (da) |
| NZ (1) | NZ630914A (da) |
| RU (1) | RU2667960C2 (da) |
| WO (1) | WO2013158868A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| LT2364360T (lt) | 2008-11-13 | 2017-08-10 | Nogra Pharma Limited | Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai |
| WO2013037970A1 (en) | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| ES2704092T3 (es) * | 2014-04-30 | 2019-03-14 | Procter & Gamble | Composición limpiadora |
| WO2015169966A2 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| CN107406851A (zh) | 2014-10-17 | 2017-11-28 | 诺格尔制药有限公司 | 利用smad7反义寡核苷酸治疗受试者的方法和组合物 |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| EP3165593B1 (en) * | 2015-10-29 | 2019-01-23 | The Procter and Gamble Company | Liquid detergent composition |
| WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
| JP7495126B2 (ja) * | 2018-05-08 | 2024-06-04 | ユニヴァーシティー オブ マイアミ | 組織への治療用核酸の送達のための材料および方法 |
| US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US7700572B2 (en) | 2001-11-02 | 2010-04-20 | Giuliani International, Ltd. | SMAD7 inhibitors for the treatment of CNS diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| WO2005014782A2 (en) * | 2003-06-13 | 2005-02-17 | Alnylam Europe Ag., | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| LT1799269T (lt) | 2004-09-28 | 2016-10-25 | Quark Pharmaceuticals, Inc. | Oligoribonukleotidai ir jų naudojimo būdai alopecijos, ūminio inkstų nepakankamumo ir kitų ligų gydymui |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| WO2007039151A1 (en) | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| ES2686708T3 (es) * | 2008-04-18 | 2018-10-19 | Baxter International Inc. | Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición |
| LT2364360T (lt) * | 2008-11-13 | 2017-08-10 | Nogra Pharma Limited | Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai |
| WO2013037970A1 (en) | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| KR102232623B1 (ko) | 2013-03-15 | 2021-03-26 | 노그라 파마 리미티드 | 결장직장암의 치료 방법 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| WO2015169966A2 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| CN107406851A (zh) | 2014-10-17 | 2017-11-28 | 诺格尔制药有限公司 | 利用smad7反义寡核苷酸治疗受试者的方法和组合物 |
| CA3000569A1 (en) | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| JP2019507755A (ja) | 2016-02-24 | 2019-03-22 | ノグラ ファーマ リミテッド | Ｓｍａｄ７阻害を使用するセリアック病の処置の方法 |
| EP3562943A1 (en) | 2016-12-30 | 2019-11-06 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en active Application Filing
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko active IP Right Grant
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
-
2015
- 2015-08-11 HK HK15107742.9A patent/HK1207117A1/xx unknown
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150003824A (ko) | 2015-01-09 |
| CN104487574B (zh) | 2017-07-07 |
| MX2014012650A (es) | 2015-04-08 |
| HK1207117A1 (en) | 2016-01-22 |
| MX370149B (es) | 2019-12-03 |
| EP2839004A1 (en) | 2015-02-25 |
| JP2015514778A (ja) | 2015-05-21 |
| JP6348484B2 (ja) | 2018-06-27 |
| AU2013249191A1 (en) | 2014-10-09 |
| US20190136237A1 (en) | 2019-05-09 |
| EP2839004B1 (en) | 2019-06-12 |
| RU2667960C2 (ru) | 2018-09-25 |
| US20150315573A1 (en) | 2015-11-05 |
| NZ630914A (en) | 2017-01-27 |
| WO2013158868A1 (en) | 2013-10-24 |
| AU2013249191B2 (en) | 2019-01-03 |
| ES2732252T3 (es) | 2019-11-21 |
| US10443056B2 (en) | 2019-10-15 |
| CA2870547A1 (en) | 2013-10-24 |
| CN104487574A (zh) | 2015-04-01 |
| JP2018131468A (ja) | 2018-08-23 |
| US20200239884A1 (en) | 2020-07-30 |
| RU2014146170A (ru) | 2016-06-10 |
| IN2014DN08158A (da) | 2015-05-01 |
| US10081809B2 (en) | 2018-09-25 |
| CN107252492A (zh) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2839004T3 (da) | Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation | |
| DK3295942T3 (da) | Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion | |
| DK2855667T3 (da) | Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2679354T3 (da) | Indretning og fremgangsmåde til automatiseret håndtering af emner | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| DK3677271T3 (da) | Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider | |
| DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
| DK2838900T3 (da) | Forbindelser og fremgangsmåder til antiviral behandling | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| DK2892912T3 (da) | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf | |
| DK2638149T3 (da) | Immortalisering af epitelceller og fremgangsmåder til anvendelse | |
| DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
| DK2867422T3 (da) | Anordning til armering af sammenføjninger og søjler i kombination | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri | |
| DK2771022T3 (da) | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| DK2658965T3 (da) | Fremgangsmåde til fremstilling af inducerede pluripotente stamceller og differentierede celler | |
| DK3080353T3 (da) | Fremgangsmåde til oprensning og isolering af lignin | |
| DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK2702992T3 (da) | Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis | |
| DK2889365T3 (da) | Fremgangsmåde til undersøgelse af mikroorganismer og indretning dertil |